Supplementary Table S2. Univariate analysis of the association of each anti-tuberculosis drug use with death*

Variable		Drug given	Drug not given	p-value
Bedaquiline	Susceptible strain†	28/157 (17.8)	166/769 (21.6)	0.292
Linezolid	Susceptible strain†	40/236 (17.0)	148/670 (22.1)	0.094
Ofloxacin	Susceptible strain	1/3 (33.3)	46/188 (24.5)	0.724
	Resistant strain	4/10 (40.0)	143/725 (19.7)	0.111
Levofloxacin	Susceptible strain	14/108 (13.0)	47/171 (27.5)	0.004
	Resistant strain	42/174 (24.1)	91/473 (19.2)	0.172
Moxifloxacin	Susceptible strain	31/207 (15.0)	43/157 (27.4)	0.004
	Resistant strain	46/249 (18.5)	74/313 (23.6)	0.137
Cycloserine	Susceptible strain	93/594 (15.7)	57/146 (39.0)	<0.001
	Resistant strain	23/119 (19.3)	21/67 (31.3)	0.064
Delamanid	Susceptible strain†	19/108 (17.6)	175/818 (21.4)	0.362
Ethambutol	Susceptible strain	46/218 (21.1)	42/110 (38.2)	0.001
	Resistant strain	38/276 (13.8)	68/322 (21.1)	0.019
Pyrazinamide	Susceptible strain	70/374 (18.7)	39/107 (36.5)	<0.001
	Resistant strain	39/260 (15.0)	46/185 (24.9)	0.009
Streptomycin	Susceptible strain	24/167 (14.4)	107/415 (25.8)	0.003
	Resistant strain	10/42 (23.8)	53/302 (17.6)	0.326
Amikacin	Susceptible strain	28/138 (20.3)	120/604 (19.9)	0.911
	Resistant strain	3/14 (21.4)	43/170 (25.3)	0.748
Kanamycin	Susceptible strain	34/248 (13.7)	108/462 (23.4)	0.002
	Resistant strain	8/41 (19.5)	44/175 (25.1)	0.448
Meropenem	Susceptible strain†	14/43 (32.6)	180/883 (20.4)	0.055
Prothionamide	Susceptible strain	83/484 (17.2)	55/173 (31.8)	<0.001
	Resistant strain	26/141 (18.4)	30/128 (23.4)	0.313
Para-aminosalicylic acid	Susceptible strain	45/245 (18.4)	103/403 (25.6)	0.034
	Resistant strain	9/69 (13.0)	37/209 (17.7)	0.366

Values are presented as number of patients who died/total number of patients (%).
*Tuberculosis-related and non-tuberculosis-related death during treatment and within 12 months after treatment completion; comparator is treatment success. †Probable susceptible strain; isolates before 2016 and 2017 were assumed to be susceptible to linezolid and bedaquiline, respectively, and all isolates were assumed to be susceptible to delamanid and meropenem.